

Please refer to the **What to Start** section of the Adult Guidelines for more detailed discussions.

**Appendix Table 5. Characteristics of Fusion Inhibitors (Updated January 29, 2008)**

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Enfuvirtide (T20)/ FUZEON</b>	<ul style="list-style-type: none"> <li>Injectable – in lyophilized powder</li> <li>Each vial contains 108 mg of enfuvirtide, reconstitute with 1.1 mL of Sterile Water for injection for delivery of approximately 90mg/1 mL</li> </ul>	90mg (1 mL) subcutaneously BID	Not applicable	Not applicable	3.8 hours	Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool	Store at room temperature (up to 25°C or 77°F) Reconstituted solution should be stored under refrigeration at 2°C–8°C (36°F–46°F) and used within 24 hours	<ul style="list-style-type: none"> <li>Local injection site reactions – almost 100% of patients (pain, erythema, induration, nodules and cysts, pruritus, ecchymosis)</li> <li>Increased bacterial pneumonia</li> <li>Hypersensitivity reaction (&lt;1%) - symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases; rechallenge is not recommended</li> </ul>

**Appendix Table 6. Characteristics of CCR5 Antagonists (Updated January 29, 2008)**

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Maraviroc (MVC)/ SELZENTRY</b>	150mg, 300mg tablets	<ul style="list-style-type: none"> <li><b>150mg BID</b> when given with strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except tipranavir/ritonavir)</li> <li><b>300mg BID</b> when given with NRTIs, enfuvirtide, tipranavir/ritonavir, nevirapine, and other drugs that are not strong CYP3A inhibitors</li> <li><b>600mg BID</b> when given with CYP3A inducers, including efavirenz, rifampin, etc. (without a CYP3A inhibitor)</li> </ul>	No food effect; take with or without food	23% for 100mg dose and 33% (predicted) for 300mg	14–18 hrs	Cytochrome P450 (CYP3A substrate)	Room temperature	Abdominal pain, cough, dizziness, musculoskeletal symptoms, pyrexia, rash, upper respiratory tract infections, hepatotoxicity, orthostatic hypotension.

**Appendix Table 7. Characteristics of Integrase Inhibitors (Updated January 29, 2008)**

Generic Name (abbreviation)/ Trade Name	Formulation	Dosing Recommendations	Food Effect	Oral Bio-availability	Serum half-life	Route of Metabolism	Storage	Adverse Events
<b>Raltegravir (RAL)/ ISENTRESS</b>	400mg tablets	400mg BID	Take with or without food	Not established	≈ 9 hrs	UGT1A1-mediated glucuronidation	Room temperature	Nausea, headache, diarrhea, pyrexia, CPK elevation